



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018. INDIA.**
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • **CIN:** L24230MH1960PLC011586

11th November, 2021

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Fort, Mumbai - 400 001

Ref: Scrip Code No. 506260

Sub: Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30.09.2021

Please find enclosed herewith the copy of newspaper advertisement with respect to the Unaudited Financial Results for the quarter and half year ended September 30, 2021, published in the Financial Express and Mumbai Lakshadeep on Thursday, November 11, 2021 in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly acknowledge the receipt and take the same on record.

Thanking you,

Yours faithfully,
For **Anuh Pharma Limited**

A.S. Ambrale
Ashwini Ambrale
Company Secretary & Compliance Officer
(Membership No.: A32456)



Encl: As above



We Serve Since 1932

Factory : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. **Tel.:** +91-7410055574 / 75

ANUH PHARMA LIMITED							
CIN: L24230MH1960PLC011566							
Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018							
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com							
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021							
(₹ in Lakhs)							
Particulars	3 months ended 30/09/2021 Unaudited	3 months ended 30/06/2021 Unaudited	3 months ended 30/09/2020 Unaudited	6 months ended 30/09/2021 Unaudited	6 months ended 30/09/2020 Unaudited	12 months ended 31/03/2021 Audited	
Total Revenue from Operation	10,874.04	11,727.17	11,223.54	22,601.21	23,648.31	43,196.01	
Net Profit/(Loss) for the period before tax	1,103.31	711.43	989.00	1,814.74	3,219.16	8,855.14	
Net Profit/(Loss) for the period after tax	859.74	559.03	663.83	1,418.77	2,335.93	2,843.63	
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	864.12	555.54	647.55	1,419.66	2,330.24	2,843.63	
Paid up Equity Share Capital (face value of Rs 5/- per share)	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60	
Other Equity (Excluding revaluation reserve)	-	-	-	-	-	16,558.75	
Earnings per equity share (Non annualised) (In Rs.) (Refer note no. 3 below)							
- Basic Rs.	1.72	1.12	1.32	2.83	4.66	5.67	
- Diluted Rs.	1.72	1.12	1.32	2.83	4.66	5.67	
1. The above is an extract of the detailed format of Financial Results for the quarter and half year ended on September 30, 2021, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter and half year ended on September 30, 2021 is available on the Stock Exchange website viz. www.bseindia.com and on the Company's website i.e. www.anuhpharma.com.							
2. Other Financial Indicators							
(₹ in Lakhs)							
Particulars	3 months ended 30/09/2021	3 months ended 30/06/2021	3 months ended 30/09/2020	6 months ended 30/09/2021	6 months ended 30/09/2020	12 months ended 31/03/2021	
EBITDA	1,438.78	1,028.16	1,409.73	2,466.94	4,057.74	5,512.17	
% of EBITDA Margin	13.23	8.77	12.56	10.92	17.16	12.78	
EBITDA (Adjusted to Forex gain / loss and mark to market on investment in Mutual funds)	1,318.52	1,049.59	1,530.02	2,368.10	4,266.56	5,372.46	
% of Adjusted EBITDA Margin	12.13	8.95	13.63	10.48	18.04	12.44	
3. On 22/09/2020, the Company passed a circular resolution for allotment of 2,50,56,000 Equity Shares of Rs. 5/- each as fully paid-up Bonus Equity Shares in the ratio of 1:1 to all registered shareholders as on the record date. Consequently, in accordance with Ind AS 33 "Earnings per Share", the basic and diluted earnings per share for all the periods presented above have been adjusted to give effect to the aforesaid issue of Bonus Shares.							
For Anuh Pharma Limited							
Sd/- Ritesh Shah Joint Managing Director (DIN: 02498729)							
Place : Mumbai Date : November 10, 2021							

Oxyzo Financial Services Private Limited							
Registered office: Shop No. G-22C (UGF) D-1 (K-84) Green Park Main, New Delhi-110016							
Tel. No: 011-40507973, Website: www.oxyzo.in, CIN: U65929DL2016PTC036174							
Extract of Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2021							
(Regulation 52 (B), read with Regulation 52 (4), of the SEBI (LODR) Regulations, 2015)							
(All amounts in Rupees lakhs, unless otherwise stated)							
Sr. No.	Particulars	Quarter ended 30 June 2021 (Unaudited)	Quarter ended 30 June 2021 (Unaudited)	Quarter ended 30 September 2021 (Unaudited)	Quarter ended 30 September 2021 (Unaudited)	Year ended 31 March 2021 (Audited)	
1	Total Income from Operations	7,282.74	6,269.39	13,552.13	8,984.62	19,752.97	
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	2,100.43	1,883.75	3,984.18	2,413.63	5,381.68	
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	2,100.43	1,883.75	3,984.18	2,413.63	5,381.68	
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,557.50	1,394.85	2,952.35	1,800.38	3,993.69	
5	Total comprehensive income for the period	1,557.14	1,394.48	2,951.62	1,800.38	3,992.46	
6	Paid up Equity Share Capital	5,118.37	5,010.34	5,118.37	4,860.12	5,010.34	
7	Reserves (excluding Revaluation Reserve)	47,880.24	41,388.46	47,880.24	31,328.43	39,951.31	
8	Securities Premium Account	38,151.55	33,259.58	38,151.55	26,912.04	33,259.58	
9	Net worth	52,998.61	46,398.80	52,998.61	36,188.55	44,961.65	
10	Paid up Debt Capital/ Outstanding Debt	143,066.74	113,407.45	143,066.74	75,188.98	116,837.57	
11	Debt Equity Ratio	2.70	2.44	2.70	2.08	2.60	
12	Earnings per share (nominal value of share Rs. 10 each):						
	Basic (in Rupees)*	3.09	2.78	5.87	3.77	8.29	
	Diluted (in Rupees)*	3.09	2.78	5.87	3.77	8.29	
* Not annualised for the half year and quarter ended.							
Note:							
a) The above is an extract of the detailed format of quarterly and half yearly financial results filed with the Stock Exchanges under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and half yearly financial results are available on the websites of the Stock Exchange(s) and at our website www.oxyzo.in.							
b) For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to Bombay Stock Exchange and can be accessed on the website.							
c) The above results are reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 9 th November, 2021.							
d) In compliance with Regulation 52 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, a limited review of financial results for the quarter and half year ended 30 th September, 2021 has been carried out by the Statutory Auditors.							
e) The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.							
For OXYZO Financial Services Private Limited							
Sd/- Ruchi Kalra Whole time Director and Chief Financial Officer (DIN: 03103474)							
Place : Gurugram Date: 09 November 2021							

Vistaar Financial Services Pvt Ltd			
CIN: U67120KA1991PTC059126 Address: Plot No 59 & 60 - 23, 22nd Cross, 29th Main BTM Layout, 2nd Stage Bengaluru 560076. Ph: 080-46669000 Email: contacts@vistaarfinance.com			
STATEMENT OF UNAUDITED FINANCIAL RESULTS			
(Rs. in Lakhs)			
Particulars	Quarter ended 30 September 2021 (refer note 3 below)	Year ended 31 March 2021 Audited	
1. Total Income from Operations	9,895	39,806	
2. Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	2,043	8,601	
3. Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	2,043	8,601	
4. Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	1,519	6,476	
5. Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income(after tax)]	1,657	6,153	
6. Paid-up equity share capital (including Class A equity share capital) (Face value of the share is ₹ 10 each)	799	799	
7. Reserves excluding Revaluation Reserves	66,361	63,584	
8. Securities Premium Account	40,547	40,547	
9. Net worth	73,123	70,346	
10. Paid up debt capital/ Outstanding debt	152,628	147,442	
11. Outstanding redeemable preference shares	Nil	Nil	
12. Debt/ Equity Ratio	2.09	2.10	
13. Earnings Per Share (EPS)			
- Basic	2.21	9.41	
- Diluted	2.19	9.34	
14. Capital redemption reserve	Nil	Nil	
15. Debenture redemption reserve (refer note 9 below)	Nil	Nil	
16. Debt Service Coverage Ratio	0.96	0.90	
17. Interest Service Coverage Ratio	1.45	1.60	

Notes:			
1. The above is an extract of the detailed format of half yearly results filed with the Stock Exchanges under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the half yearly financial results are available on the websites of the Stock Exchange(s) and the listed entity (URL - http://www.vistaarfinance.com/investors.php).			
2. For the other line items referred in regulation 52(4) of the LODR regulations, pertinent disclosures have been made to the Stock Exchange(s) and can be accessed on the URL - http://www.vistaarfinance.com/investors.php			
3. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of Vistaar Financial Services Private Limited ("the Company") at their respective meetings held on 09 November 2021 and 10 November 2021 respectively.			
4. The impact of the COVID-19 pandemic including the "second wave" and its possible consequential implications on Company's operations and financial metrics, including the estimates of impairment of loans will depend on future developments, which are highly uncertain. Management continues to monitor the evolving situation and has considered events up to the date of these financial results to determine the financial implications including in respect of Expected Credit Loss (ECL) provisioning as at September 30, 2021. The Company has made cumulative ECL provisions on loans aggregating to Rs. 6,134 lakhs (March 31, 2021 - Rs. 7,337 lakhs) including a management overlay of Rs. 1,572 lakhs (March 31, 2021 - Rs. 4,525 lakhs). Given the dynamic and evolving nature of the pandemic, these estimates are subject to uncertainty caused by the ongoing Covid 19 pandemic including its severity and duration and other related events.			
5. In compliance with Regulation 52 of the Securities Exchange Board of India (SEBI) (Listing obligations and Disclosure requirements) Regulations 2015, a limited review of the financial results for the quarter and six months ended September 30, 2021 has been carried out by the statutory auditors. The amounts of quarter ended 30 September 2021 are the balancing amounts between the unaudited amounts in respect of the half year ended 30 September 2021 and 30 June 2021. The quarterly results for quarter ended 30 June 2021 was not subjected to limited review or audit by the statutory Auditors.			
6. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.			
7. "The Code on Social Security 2020" ("the Code") relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published."			
8. The Company is primarily engaged in the business of financing and as such no separate information is required to be furnished in terms of Ind AS 108 "Operating segments" specified under section 133 of the Companies Act, 2013.			
9. Debenture Redemption Reserve (DRR) - No DRR is required in respect of privately placed debentures in terms of Rule 18(7)(b)(ii) of the Companies (Share Capital and Debenture) Rules, 2014.			
For and on behalf of the Board of Directors			
Sd/- Brahmanand Hegde Executive Vice Chairman DIN : 02984527			
Place: Bangalore Date: 10 November 2021			



ANUPAM RASAYAN INDIA LTD.

CIN - L24231GJ2003PLC042988

Regd. office: Anupam Rasayan India Ltd. 8110, Sachin G.I.D.C. Estate, Sachin, Surat - 394230, Gujarat, India. Tel: +91 261 2398991-95, Website: www.anupamrasayan.com, Email: investors@anupamrasayan.com

1. Extract from the Unaudited Consolidated Financial Results of Anupam Rasayan India Ltd. for the quarter ended September 30, 2021

(Rs. in millions except per share data)						
Particulars	Quarter ended			Half Year Ended		Year Ended
	30-Sep-21 Unaudited	30-Jun-21 Unaudited	30-Sep-20 Unaudited	30-Sep-21 Unaudited	30-Sep-20 Audited	31-Mar-21 Audited
Total Revenue	2,551.62	2,379.68	2,389.85	4,931.30	3,735.99	8,373.21
Net Profit / (Loss) (before Tax & Exceptional items)	502.00	439.65	336.28	941.65	355.57	1,000.03
Net Profit / (Loss) before Tax (after Exceptional items)	502.00	439.65	336.28	941.65	355.57	1,000.03
Net Profit / (Loss) (after Tax & Exceptional items)	360.53	321.21	262.80	681.73	265.06	702.96
Total Comprehensive Income	358.40	311.75	257.00	670.15	257.35	695.49
Share Capital	999.22	999.22	517.70	999.22	517.70	999.22
Reserves (excluding Revaluation Reserves) as shown in the Audited Balance Sheet	-	-	-	-	-	14,734.80
Earnings Per Share Basic & Diluted (Face Value of Rs. 5/- each)						
(-) Basic EPS (Rs.)	3.61	3.21	5.25	6.82	5.30	8.56
(-) Diluted EPS (Rs.)	3.59	3.20	3.36	6.79	3.39	8.56

2. Extract from the Unaudited Standalone Financial Results of Anupam Rasayan India Ltd. for the quarter ended September 30, 2021

(Rs. in millions except per share data)						
Particulars	Quarter ended			Half Year Ended		Year Ended
	30-Sep-21 Unaudited	30-Jun-21 Unaudited	30-Sep-20 Unaudited	30-Sep-21 Unaudited	30-Sep-20 Audited	31-Mar-21 Audited
Total Revenue	2,551.62	2,379.68	2,389.55	4,931.30	3,735.67	8,373.19
Net Profit / (Loss) (before Tax & Exceptional items)	496.32	437.05	332.94	933.37	352.48	994.24
Net Profit / (Loss) before Tax (after Exceptional items)	496.32	437.05	332.94	933.37	352.48	994.24
Net Profit / (Loss) (after Tax & Exceptional items)	358.27	319.78	260.34	678.04	262.95	699.21
Total Comprehensive Income	356.14	310.32	254.54	666.47	255.25	691.75
Share Capital	999.22	999.22	517.70	999.22	517.70	999.22
Reserves (excluding Revaluation Reserves) as shown in the Audited Balance Sheet	-	-	-	-	-	14,726.86
Earnings Per Share Basic & Diluted (Face Value of Rs. 5/- each)						
(-) Basic EPS (Rs.)	3.59	3.20	5.21	6.79	5.26	8.51
(-) Diluted EPS (Rs.)	3.57	3.19	3.33	6.76	3.36	8.51

- [1] The above financial results for the quarter and half year ended September 30, 2021 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 10, 2021. An interim review of the above results has been carried out by the statutory auditors of the Company. The full format of the Quarterly Financial results are available on the stock exchanges website: www.bseindia.com and www.nseindia.com and also on the company's website: www.anupamrasayan.com.
- [2] Based on the management approach as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the company's performance and allocates resources based on an analysis of various performance indicators of business segment/s in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence, disclosure of segment-wise information is not required and accordingly not provided.
- [3] The Company has taken into account the potential impacts of Covid-19 in the preparation of financial results. Based on the information currently available there is no material impact on the carrying amount of assets and hence no provision for any impairment is required. As the situation unfolds in future, the eventual impact may be different from the estimates made as on the date of approval of these Financial Results.
- [4] The Board of Directors have recommended an interim dividend of INR 0.50 at 5% per equity share of INR 10/- each.
- [5] The figures of the previous period have been re-grouped/rearranged and/or recasted wherever considered necessary.

For ANUPAM RASAYAN INDIA LIMITED

Place: Surat
Date: November 10, 2021

Anand Desai
Managing Director

Adfactors 416

INTERNATIONAL CENTRE FOR AUTOMOTIVE TECHNOLOGY

Plot No. 26, Sector-3, MET Manesar, Gurgaon - 122050.

TENDER NOTICE

